SequelSEC

NANOVIRICIDES, INC. NNVC

Pharmaceutical Preparations · CIK 0001379006 · Fiscal year ends 0630

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2026-06-30
Operating income
-$8.31M
Fiscal year ended 2026-06-30
Free cash flow
-$7.78M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$21.53MMarket value of stock held by non-affiliates, as stated on the cover page for 2024-12-31
Float per share$1.24Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / equity2.9×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2024-12-31, not today, and each multiple below it uses the figures for the fiscal year ending 2025-06-30 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio2.66x19th

NANOVIRICIDES, INC. (NNVC) reported revenue of $0 and net income of -$8.22M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from NANOVIRICIDES, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

NANOVIRICIDES, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$0
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$8.31M
Net income-$8.22M
Research & development$4.71M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$3.60M
Selling & marketingUnavailable

Balance

NANOVIRICIDES, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$2.79M
Total assets$9.87M
Current assets$3.16M
Total liabilities$1.20M
Current liabilities$1.19M
Total equity incl. NCI$8.68M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payableUnavailable

Cash flow

NANOVIRICIDES, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$7.70M
Capital expenditures$84.32K
Investing cash flow-$84.32K
Financing cash flow$9.02M
Net change in cashUnavailable
Stock-based compensationUnavailable
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

NANOVIRICIDES, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$7.78M
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio2.66x
Revenue YoY growthUnavailable
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NNVC in the interactive workspace to inspect any figure back to its filing.

Source filings

10-K · Filed 2026-09-28View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-Q · Filed 2026-02-17View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-K · Filed 2025-09-29View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.